Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| NASDAQ | USD | Real-time | ||
| OTC Markets | USD | Delayed | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
(Reuters) - AstraZeneca (NASDAQ:AZN) said on Thursday a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an...
SEOUL (Reuters) – South Korea on Thursday authorised AstraZeneca PLC’s antibody-based therapy for preventing COVID-19 infection in people with a poor immune response,...
(Reuters) – Drugmaker AstraZeneca said on Thursday its cancer drug Imfinzi, when given along with neoadjuvant chemotherapy in a late-stage trial, showed promise in helping...
The stocks of the vaccine producers have gained a lot during 2021 due to the wide vaccination campaign around the world. Still, the COVID-19 pandemic is still not over as the virus...
It’s a pretty flat though mildly positive start to trade in Europe again after a decent handover from Asia, whilst Wall Street again registered fresh all-time highs. The S&P 500...
Here is a list of companies that were popular on the site in the latest week.Argo BlockchainUK listed cryptocurrency miner Argo Blockchain (LON:ARB) was popular after the company...
AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Buy | Strong Buy | Buy |
| Technical Indicators | Strong Sell | Sell | Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Sell | Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 228.40 | 236.20 | 227.80 | -9.20 | -3.87% | 1.88M | London | |||
| 374.80 | 388.20 | 368.40 | -11.60 | -3.00% | 1.46M | London | |||
| 2,320.00 | 2,380.00 | 2,275.00 | -80.0 | -3.33% | 47.31K | London | |||
| 2,478.00 | 2,499.00 | 2,382.00 | -64.0 | -2.52% | 1.08M | London | |||
| 14.00 | 14.00 | 14.00 | 0.00 | 0.00% | 5.48K | London | |||
| 173.80 | 174.80 | 168.60 | -1.80 | -1.02% | 449.36K | London | |||
| 0.175 | 0.175 | 0.175 | -0.0850 | -32.69% | 21.09M | London | |||
| 17.90 | 18.75 | 17.65 | -0.60 | -3.24% | 2.32M | London | |||
| 0.58 | 0.58 | 0.58 | 0.00 | 0.00% | 0.00 | London | |||
| 2,719.00 | 2,792.00 | 2,698.00 | -79.0 | -2.82% | 825.84K | London | |||
| 1,344.00 | 1,372.00 | 1,340.00 | -22.00 | -1.61% | 212.37K | London | |||
| 0.674 | 0.798 | 0.42 | +0.164 | +32.16% | 412.17M | London | |||
| 82.44 | 84.70 | 76.40 | +3.58 | +4.54% | 5.84M | London | |||
| 134.00 | 134.00 | 134.00 | -2.50 | -1.83% | 109.08K | London | |||
| 135.50 | 138.40 | 129.50 | -4.60 | -3.28% | 6.41M | London |